AC
SBFM

Armistice Capital’s Sunshine Biopharma SBFM Stock Holding History

Armistice Capital’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-107
Closed -$578K – 403
2023
Q4 		$578K Buy
107
+58
+118% +$330K 0.01% 195
2023
Q3 		$312K Sell
49
-61
-55% -$546K ﹤0.01% 181
2023
Q2 		$1.08M Buy
+110
New +$1.33M 0.02% 159
2022
Q2 		– Sell
-32
Closed -$1.56M – 198
2022
Q1 		$1.56M Buy
+32
New +$1.56M 0.03% 103

Other funds holding SBFM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital's SBFM Position: Q1 2024 in Review

Armistice Capital sold out of Sunshine Biopharma (SBFM) in Q1 2024, closing a stake of 107 shares — an estimated $578K sold.

Armistice Capital first reported a position in SBFM in Q1 2022 and held it in 4 quarters. The position peaked at $1.56M in Q1 2022. 10 funds tracked by Wall St. Rank hold SBFM as of Q1 2024.

  • Armistice Capital reported no remaining Sunshine Biopharma position as of Q1 2024 after selling out during the quarter.
  • Armistice Capital sold 107 Sunshine Biopharma shares in Q1 2024, an estimated $578K.
  • Armistice Capital first reported a position in Sunshine Biopharma in Q1 2022 and held it in 4 quarters.
  • Armistice Capital's Sunshine Biopharma position peaked at $1.56M in Q1 2022.
  • 10 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.